Physician profile
Gary Langieri
NPI 1336139724
$7,030.35
in general payments reported to CMS, 2019-2025
19 companies · $1,204 in 2025
The $1,204 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $458 · 2021: $655 · 2022: $455 · 2023: $233 · 2024: $3,537 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Travel and Lodging: $2,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.36 |
| Travel and Lodging | $2,208.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,678.55 | 2021-2025 | Aveir |
| Boston Scientific Corporation | $1,563.69 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Farapulse |
| Pfizer INC. | $829.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $340.42 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $305.20 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $284.82 | 2019-2025 | Lifevest |
| Atricure, INC. | $282.89 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $149.59 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $129.56 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $113.58 | 2025 | Onpattro |
| Novo Nordisk INC | $77.45 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Biotronik INC. | $74.50 | 2019-2020 | |
| Amgen INC. | $50.87 | 2019-2023 | Repatha |
| Medtronic, INC. | $35.67 | 2024 | Linq II |
| Lundbeck LLC | $33.60 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $25.71 | 2025 | |
| Chiesi USA, INC. | $22.05 | 2025 | Kengreal |
| Esperion Therapeutics, INC. | $17.20 | 2025 | Nexletol |
| Edwards Lifesciences Corporation | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Langieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.